Cargando…
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL
BACKGROUND: Next-generation sequencing (NGS) of the rearranged immunoglobulin heavy-chain gene has emerged as a highly sensitive method to detect minimal residual disease (MRD) in B acute lymphoblastic leukemia/lymphoma (B-ALL). However, a sensitive and easily implemented NGS methodology for routine...
Autores principales: | Cheng, Shuhua, Inghirami, Giorgio, Cheng, Shuo, Tam, Wayne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103872/ https://www.ncbi.nlm.nih.gov/pubmed/30134947 http://dx.doi.org/10.1186/s13045-018-0652-y |
Ejemplares similares
-
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL
por: Locatelli, Franco, et al.
Publicado: (2022) -
Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking
por: Cheng, Shuhua, et al.
Publicado: (2021) -
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse
por: Short, Nicholas J., et al.
Publicado: (2022) -
P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
por: Jentzsch, Madlen, et al.
Publicado: (2023) -
P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
por: Askeland, F. B., et al.
Publicado: (2022)